

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Currently Amended) An isolated polypeptide consisting of ~~an~~ the amino acid sequence ~~selected from the group consisting of SEQ ID NO:333.~~
(a) ~~sequences set forth in SEQ ID NOs:241, 332-336, 342-346, 391-395, and 409-413.~~
- 3.-10. (Canceled)
11. (Previously Presented) A composition comprising the polypeptide of claim 2 in combination with a pharmaceutically acceptable carrier or excipient.
- 12.-30. (Canceled)
31. (Currently Amended) A composition comprising a polypeptide according to claim 2 and ~~MPL-SE~~ monophosphoryl lipid A.
- 32.-34 (Canceled)
35. (Previously Presented) A composition comprising the polypeptide of claim 2 in combination with a non-specific immune response enhancer.
36. (Previously Presented) The composition according to claim 35 wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.

37. (Canceled)

38. (New) The composition according to claim 31, further comprising an aluminum salt.

39. (New) A composition comprising a polypeptide according to claim 2 and 3-de-O-acylated monophosphoryl lipid A.

40. (New) The composition according to claim 40, further comprising an aluminum salt.

41. (New) A composition comprising a polypeptide according to claim 2 and an adjuvant containing monophosphoryl lipid A.